Efficacy and Safety of Testosterone Treatment in Men: An Evidence Report for a Clinical Practice Guideline by the American College of Physicians
- 7 January 2020
- journal article
- review article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 172 (2), 105-+
- https://doi.org/10.7326/m19-0830
Abstract
Testosterone treatment rates in adult men have increased in the United States over the past 2 decades. To assess the benefits and harms of testosterone treatment for men without underlying organic causes of hypogonadism. English-language searches of multiple electronic databases (January 1980 to May 2019) and reference lists from systematic reviews. 38 randomized controlled trials (RCTs) of at least 6 months' duration that evaluated transdermal or intramuscular testosterone therapies versus placebo or no treatment and reported prespecified patient-centered outcomes, as well as 20 long-term observational studies, U.S. Food and Drug Administration review data, and product labels that reported harms information. Data extraction by a single investigator was confirmed by a second, 2 investigators assessed risk of bias, and evidence certainty was determined by consensus. Studies enrolled mostly older men who varied in age, symptoms, and testosterone eligibility criteria. Testosterone therapy improved sexual functioning and quality of life in men with low testosterone levels, although effect sizes were small (low- to moderate-certainty evidence). Testosterone therapy had little to no effect on physical functioning, depressive symptoms, energy and vitality, or cognition. Harms evidence reported in trials was judged to be insufficient or of low certainty for most harm outcomes. No trials were powered to assess cardiovascular events or prostate cancer, and trials often excluded men at increased risk for these conditions. Observational studies were limited by confounding by indication and contraindication. Few trials exceeded a 1-year duration, minimum important outcome differences were often not established or reported, RCTs were not powered to assess important harms, few data were available in men aged 18 to 50 years, definitions of low testosterone varied, and study entry criteria varied. In older men with low testosterone levels without well-established medical conditions known to cause hypogonadism, testosterone therapy may provide small improvements in sexual functioning and quality of life but little to no benefit for other common symptoms of aging. Long-term efficacy and safety are unknown. American College of Physicians. (PROSPERO: CRD42018096585)Funding Information
- American College of Physicians
This publication has 132 references indexed in Scilit:
- Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trialsBMC Medicine, 2013
- Clinical Meaningfulness of the Changes in Muscle Performance and Physical Function Associated With Testosterone Administration in Older Men With Mobility LimitationThe Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 2011
- Gait Speed and Survival in Older AdultsJAMA, 2011
- Adverse Events Associated with Testosterone AdministrationThe New England Journal of Medicine, 2010
- Effects of Transdermal Testosterone on Bone and Muscle in Older Men with Low Bioavailable Testosterone Levels, Low Bone Mass, and Physical FrailtyJournal of the American Geriatrics Society, 2010
- Effects of Testosterone on Muscle Strength, Physical Function, Body Composition, and Quality of Life in Intermediate-Frail and Frail Elderly Men: A Randomized, Double-Blind, Placebo-Controlled StudyJournal of Clinical Endocrinology & Metabolism, 2010
- Measuring inconsistency in meta-analysesBMJ, 2003
- The PHQ-9Journal of General Internal Medicine, 2001
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992
- Development and validation of a geriatric depression screening scale: A preliminary reportJournal of Psychiatric Research, 1983